RARA CRAFT DATABASE for FDA Medical Devices

From a Manufacturing Site to Test Breakpoints: What September 2026's Eighteen PCCPs Plan to Change

日本語版

On September 28, 2026, bioMérieux's VITEK 2 AST cefepime card for Streptococcus (K260619) was cleared under a 510(k) with a Predetermined Change Control Plan (PCCP) attached. The 510(k) Summary never mentions it. FDA's clearance letter names the plan, "Predetermined Change Control Plan for Breakpoint Evaluations, Version 01.B." And FDA's Decision Summary, the review record it publishes alongside the clearance, explains it: the plan is a breakpoint change protocol that FDA reviewed and accepted in April 2025 on a different product, K250274. Nothing about retraining a model.

PCCPs are usually discussed as an AI mechanism, and FDA's best-known guidance on them is the one for AI-enabled device software functions. Of the eighteen decisions in September 2026 that carry a PCCP, RA Craft Database can confirm AI/ML from the public documents for seven; one De Novo has "AI" in its name; eight have no AI or machine-learning language in their documents; for two, AI use cannot be confirmed from public information. By what the plans cover, retraining an AI model sits alongside re-evaluating breakpoints, adding operating systems and data connections, changing a manufacturing site and extending use to more laboratories. This article keeps three things apart: whether the device uses AI, what the plan covers, and which public document confirms it.

Fifteen of the eighteen are 510(k)s, two are PMA supplements, one is a De Novo. Month by month in 2026, PCCP-flagged decisions ran 7, 12, 9, 10, 10, 13, 18, 16 and 18 from January to September, so the count has stayed at 16 to 18 a month since July (RA Craft Database records; see the note at the end for how they were counted). This is the first part of our monthly PCCP series. Article No.9 covers what a PCCP is; this one goes through the eighteen.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles